Provided by Tiger Fintech (Singapore) Pte. Ltd.

STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD

24.62
-0.9500-3.72%
Post-market: 24.51-0.1071-0.44%18:09 EDT
Volume:684.39K
Turnover:17.19M
Market Cap:1.41B
PE:-9.51
High:26.90
Open:26.38
Low:24.30
Close:25.57
Loading ...

Structure Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Yesterday

Piper Sandler Reaffirms Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TIPRANKS
·
09 May

Structure Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
09 May

Structure Therapeutics Reports Q1 2025 Net Loss of $46.8 Million, Up from $26 Million in Q1 2024

Reuters
·
09 May

Is Structure Therapeutics Inc. (NASDAQ:GPCR) the Most Promising Small-Cap Stock According to Analysts?

Insider Monkey
·
26 Apr

LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study

Zacks
·
21 Apr

Shares of Obesity Drug Developer Structure Therapeutics up 24.6% Premarket After Eli Lilly's Pill Leads to 7.9% Weight Loss in Late-Stage Trial

THOMSON REUTERS
·
17 Apr

NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback

Zacks
·
15 Apr

Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill

TIPRANKS
·
14 Apr

Viking, Structure rally after Pfizer halts obesity drug development

TIPRANKS
·
14 Apr

Press Release: Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results

Dow Jones
·
27 Mar

Septerna, Inc. (SEPN): Among Top Insider Purchases Last Month

Insider Monkey
·
14 Mar

Analysts Have Conflicting Sentiments on These Healthcare Companies: Fate Therapeutics (FATE), Organon (OGN) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TIPRANKS
·
06 Mar

BUZZ-Jefferies looks to Lilly data to reignite interest in obesity stocks

Reuters
·
05 Mar